Abametapir Lotion 0.74% w/w + Vehicle Lotion

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head Lice Infestation

Conditions

Head Lice Infestation

Trial Timeline

Feb 1, 2014 → Aug 1, 2014

About Abametapir Lotion 0.74% w/w + Vehicle Lotion

Abametapir Lotion 0.74% w/w + Vehicle Lotion is a phase 3 stage product being developed by Dr. Reddy's Laboratories for Head Lice Infestation. The current trial status is completed. This product is registered under clinical trial identifier NCT02060903. Target conditions include Head Lice Infestation.

What happened to similar drugs?

11 of 20 similar drugs in Head Lice Infestation were approved

Approved (11) Terminated (0) Active (9)

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02097485Phase 2Completed
NCT02060903Phase 3Completed
NCT02062060Phase 3Completed

Competing Products

20 competing products in Head Lice Infestation

See all competitors
ProductCompanyStageHype Score
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
Ha44 Gel 0.74% w/wDr. Reddy's LaboratoriesPhase 2
32
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
Abametapir Lotion 0.74% w/wDr. Reddy's LaboratoriesPhase 1
26
DFN-11 InjectionDr. Reddy's LaboratoriesPhase 2
24
Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + PlaceboDr. Reddy's LaboratoriesPhase 1
26
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 2
32
Ha44 GelDr. Reddy's LaboratoriesPhase 2
32
AFM24 + SNK01AffimedPhase 1/2
14
Cemiplimab + CetuximabEli LillyPhase 2
42
BB-401Benitec BiopharmaPhase 2
25
Placebo + LY2300559Eli LillyPhase 2
27
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
25
Patritumab + Cetuximab + Cisplatin + Carboplatin + PlaceboDaiichi SankyoPhase 2
27
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
cevimeline hydrochlorideDaiichi SankyoPhase 3
40
Docetaxel + Erlotinib + ChemotherapyAstellas PharmaPhase 2
35